



OxySure Therapeutics (OXYS) Receives Fifth of Five Incentives from City of Frisco

Frisco, Texas, USA, February 16, 2016 – OxySure Therapeutics, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen products with its “oxygen from powder” technology and other innovative emergency medical solutions today announces that the Company has received the fifth of five economic incentives from the City of Frisco through the Frisco Economic Development Corporation (“FEDC”).

The FEDC has provided OxySure a significant incentive over five years, designed to incentivize capital investment and job growth in the City. Through these incentives and with the assistance of the Company’s landlord Sinacola Commercial, OxySure has developed a multi-million dollar, purpose built production and distribution facility in the City of Frisco, where the Company produces the innovative OxySure Model 615 emergency oxygen device.

Julian Ross, CEO of OxySure stated: “We are grateful for the support we have received from the FEDC and we are proud of the manufacturing capability our facility now has to offer. We look forward to leveraging our platform as we continue to expand our business.”

“The Frisco EDC is glad to see the continued growth of OxySure Therapeutics, Inc. as a home-grown company that graduated from Frisco’s NTEC business accelerator,” said Jim Gandy, President of the Frisco EDC. “We wish OxySure continued success in growing the company.”

About OxySure Therapeutics, Inc.

OxySure Therapeutics, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. *In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products.* www.OxySure.com

About the Frisco EDC

The Frisco Economic Development Corporation (FEDC) was created in 1991, when Frisco voters approved a half-cent sales tax to fund economic development in the city. The FEDC operates as a Texas non-profit corporation and is governed by a seven-member board of directors appointed by the Frisco City Council. Job number one is creating jobs, as the FEDC’s mission is to improve the economic opportunities and quality of life for all Frisco residents. Since its establishment, the FEDC has facilitated every major economic development project in the city of Frisco, resulting in more than 340 projects that have the potential to occupy over 44 million square feet of commercial space, generate new capital investment in excess of \$7.6 billion, and create or retain more than 77,000 potential direct jobs in the city of Frisco.

Contacts:

Redchip Companies, Inc.

Jon Cunningham: jon@redchip.com

800-733-2447, ext. 107

www.redchip.com/

Frisco EDC

Darcy Schroer: DSchroer@FriscoEDC.com

972-292-5155

www.FriscoEDC.com

Forward-Looking Statements

Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management's control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Therapeutics, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Therapeutics, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Therapeutics, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2014.